BFM
BTAI icon

Boothbay Fund Management’s BioXcel Therapeutics BTAI Stock Holding History

Boothbay Fund Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,731
Closed -$2.25M – 2272
2022
Q1 		$2.25M Buy
+6,731
New +$1.95M 0.05% 531

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Boothbay Fund Management's BTAI Position: Q2 2023 in Review

Boothbay Fund Management sold out of BioXcel Therapeutics (BTAI) in Q2 2023, closing a stake of 1,688 shares — an estimated $504K sold.

Boothbay Fund Management first reported a position in BTAI in Q4 2019 and held it in 6 quarters. The position peaked at $1.9M in Q1 2020. 88 funds tracked by Wall St. Rank hold BTAI as of Q2 2023.

  • Boothbay Fund Management reported no remaining BioXcel Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 1,688 BioXcel Therapeutics shares in Q2 2023, an estimated $504K.
  • Boothbay Fund Management first reported a position in BioXcel Therapeutics in Q4 2019 and held it in 6 quarters.
  • Boothbay Fund Management's BioXcel Therapeutics position peaked at $1.9M in Q1 2020.
  • 88 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.